Prescription drug costs have become one of the fastest-growing expenses in employer-sponsored health plans. Yet despite representing a significant portion of overall healthcare spending, pharmacy benefits remain one of the least understood components of a health plan.
This article is based on a recent episode of Uncovered by DSP, where host Blake Erickson sat down with DSP Employee Benefits Practice Leader Bill Storie to pull back the curtain on one of the most misunderstood areas of healthcare spending: prescription drugs. Their discussion explored everything from pharmaceutical marketing and patent strategies to formularies, rebates, and the factors driving pharmacy costs higher for employers.
Behind every prescription is a complex network of pharmaceutical manufacturers, physicians, pharmacy benefit managers (PBMs), insurance carriers, patent laws, rebates, and formularies. Understanding how these pieces work together can help employers make more informed decisions and identify opportunities to better manage healthcare costs.
Twenty years ago, pharmaceutical marketing looked very different than it does today.
Drug representatives routinely visited physicians' offices with lunches, gifts, golf outings, and other incentives designed to build relationships and encourage prescriptions of their products. While increased government oversight and transparency requirements have significantly reduced many of these practices, the incentives have not disappeared entirely.
Today, compensation often comes in different forms. Physicians may be paid to participate in advisory boards, surveys, research studies, speaker programs, or consulting opportunities related to specific medications. While many of these activities are legitimate and valuable, they also create ongoing relationships between pharmaceutical companies and healthcare providers.
For employers funding health plans, the concern is not necessarily whether these arrangements are appropriate. The concern is whether they influence prescribing decisions that ultimately impact healthcare costs.
Many employers assume rising pharmacy costs are simply the result of inflation. The reality is much more complicated.
Medical costs often increase between 6% and 12% annually. Pharmacy costs, however, frequently trend much higher, often approaching 18% to 22% per year.
Several factors contribute to this increase:
While these innovations can improve quality of life and even cure previously untreatable conditions, they also increase overall healthcare spending.
Most people assume a prescription is based solely on clinical need. While patient care remains the priority, pharmaceutical companies have long invested heavily in influencing physician behavior.
Historically, this often involved direct gifts, entertainment, and expensive perks for top prescribers. Today, those relationships are more likely to involve advisory boards, research participation, honorariums, speaking engagements, or consulting opportunities.
The result is a healthcare system where manufacturers have significant incentives to ensure physicians remain familiar with their products, especially when multiple medications exist to treat the same condition.
For employers paying the bill, this can impact utilization patterns and ultimately influence overall pharmacy spend.
One of the biggest misconceptions among consumers is that a prescribed medication is the only option available.
In reality, multiple medications often exist to treat the same condition. Generic medications make up approximately 90% of prescriptions filled, yet account for less than 15% of overall pharmacy spending. Brand-name and specialty medications drive the majority of prescription drug costs.
Generic medications contain the same active ingredients as their brand-name counterparts and must meet strict regulatory standards. While inactive ingredients can vary slightly, there is generally little clinical difference between the two for most patients.
Unfortunately, many employees never ask whether a lower-cost alternative exists because they assume the medication prescribed by their physician is the only option.
This creates opportunities for unnecessary spending when lower-cost options may be equally effective.
When pharmaceutical companies develop new medications, they receive patent protection that prevents competitors from producing generic versions for a period of time.
These patents are designed to allow manufacturers to recover the substantial investment required for research, development, and clinical trials. However, manufacturers often seek ways to extend the profitability of successful drugs beyond their original patent timeline.
One common strategy is often referred to as "evergreening," where manufacturers:
These strategies can delay generic competition and keep prices elevated for longer periods.
For employers, that means savings expected from future generic competition may take longer to materialize.
A high-cost prescription drug looked very different 15 or 20 years ago.
At one time, a medication costing $3,000 per month was considered extraordinarily expensive. Today, many specialty medications exceed that amount, and some gene therapies can cost more than $1 million for a single treatment.
Some of these therapies represent remarkable medical breakthroughs. Certain treatments can cure conditions that once required lifelong management. Others offer life-changing outcomes for patients with rare diseases.
The challenge for employers is balancing access to innovative treatments with the long-term financial sustainability of their health plans.
As medical science continues to advance, employers are increasingly being asked to fund treatments that would have been unimaginable just a decade ago.
Many employees become frustrated when a medication covered under one health plan is excluded under another.
The answer often comes down to formulary design.
A formulary is the list of medications covered by a health plan. These lists are heavily influenced by negotiations between pharmacy benefit managers, insurance carriers, and pharmaceutical manufacturers.
Coverage decisions are not always based solely on:
Instead, they are frequently influenced by rebate agreements and manufacturer contracts. As a result, two medications that treat the same condition may receive very different coverage treatment depending on the health plan.
This helps explain why one employer's plan may cover a medication while another plan excludes it entirely.
While employers cannot control every aspect of pharmacy spending, they do have opportunities to influence outcomes.
Self-funded employers often have greater flexibility to evaluate different PBMs and pharmacy programs. Understanding how formularies are managed, how rebates are handled, and what alternatives exist can reveal opportunities for improvement.
Generic medications remain one of the most effective ways to reduce pharmacy costs without sacrificing quality of care. Plan designs that encourage generic utilization can generate meaningful savings for both employees and employers.
Many employees simply do not realize they may have lower-cost treatment options available.
Encouraging employees to have conversations with their physicians about alternative medications, generic options, and cost-saving opportunities can lead to better outcomes and lower costs.
Every employer should be asking:
Prescription drugs represent one of the most complex components of healthcare spending. Between pharmaceutical manufacturers, physicians, PBMs, carriers, patents, rebates, and formularies, it is often difficult to understand exactly what is driving costs.
The employers that achieve the best outcomes are typically the ones willing to look beyond annual renewal increases and ask deeper questions about how their pharmacy benefits are structured.
Understanding the system won't eliminate rising healthcare costs overnight, but it can help employers make more informed decisions and identify opportunities to better manage one of the fastest-growing expenses in their benefits program.
The Employee Benefits team at DSP helps employers uncover what's driving pharmacy spend, evaluate PBM arrangements, benchmark plan performance, and identify opportunities to improve outcomes while controlling costs.
If you'd like to learn more about your pharmacy program, contact DSP to start the conversation.
This article highlights key takeaways from an episode of Uncovered by DSP, where Blake Erickson and Bill Storie discuss the hidden forces influencing prescription drug costs and what employers can do to gain greater visibility into their pharmacy spend.
Watch on YouTube: https://www.youtube.com/watch?v=6sF0NqSmX9Ihttps://music.amazon.com/podcasts/54c2d33d-ae22-4d4c-9c00-13cb2495a79e/episodes/f07ef6f2-eda3-4037-b2fa-d944b6c74b52/uncovered-by-dsp-the-prescription-drug-machine-s1e3
Listen on Spotify: https://open.spotify.com/episode/5hWzuQrnsbYEzEGpqSInQ5?si=s8fOeVJ5SmOijpHego4hOA
Listen on Apple Podcasts: https://podcasts.apple.com/us/podcast/the-prescription-drug-machine-s1e3/id1885970831?i=1000770833848
Listen on Amazon Music: https://music.amazon.com/podcasts/54c2d33d-ae22-4d4c-9c00-13cb2495a79e/episodes/f07ef6f2-eda3-4037-b2fa-d944b6c74b52/uncovered-by-dsp-the-prescription-drug-machine-s1e3
Whether you're a CFO, HR leader, business owner, or benefits decision-maker, the full episode provides additional examples, stories, and insights into how the prescription drug system works behind the scenes.